Stocks · News reference
Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS)Up to $77 million in private financing consisting of $21.5
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~SAN DIEGO, CA / ACCESS Newswire / August 31, 2026 / Ensysce Biosciences, Inc.
Filed: 2026-08-25 AccNo: 0001493152-26-040080 Size: 204 KB Item 8.01: Other Events
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.50) by 60 percent. This is a 74.68 percent increase over losses of $(0.79) per share from
US stocks trade mixed, Nasdaq falls 50 points. Energy shares up 1.3%, tech stocks down 0.5%. US Foods beats earnings, Clearone Inc surges 203%.